The paradox of data in precision medicine
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
The publicly available Human Endometrial Cell Atlas could progress the development of therapeutics for endometriosis.
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s…
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
Using its AI-driven platform, Pepper Bio discovered a promising therapeutic for liver cancer. In this Q&A session with Jon Hu, CEO and co-founder of Pepper Bio, we dive into how the identification of two inhibitors led to a $135M in-licensing deal.